Molecular Diagnostics



Gene Panel Tests for Hundreds of Diseases Simultaneously
A new genetic sequencing test moves beyond assaying for one disease at a time, making it possible to identify more than 750 diseases triggered by mutations in children concomitantly and deliver results within six to eight weeks. More...16 Dec 2013

In Other News
Aggressive New HIV Strain Leads to AIDS Faster
Early Access Offered to New, Streamlined Interpretation of Patient Sequencing Data
Importance of High-Quality Controls in Assay Design and Development Examined
High-Throughput DNA Analyzer and Dedicated Cystic Fibrosis Assays Approved for Diagnostics Use in the United States
Concussion Leading to Long Term Cognitive Disability May Be Diagnosed by a Simple Blood Test
Genetic Testing Underutilized for Cardiovascular Therapy
Simple Blood Test Diagnoses Specific Lung Cancer Subtypes
Genetic Cause of Warburg Micro Syndrome Identified
Blood Test Reveals Skin Cancer Spread
A MicroRNA Elevated in Pancreatic Cancer Patients May Have Diagnostic Potential
Integrated Cervical Cancer Testing Provides Leading-Edge Solutions for New Screening Needs
Blood Levels of Genetic Material Predict Thyroid Cancer Recurrence
Biomarkers Could Lead to Early Diagnosis of Colorectal Cancer
Immunodeficiency Disorder CVID Caused by Gene Mutation
Genetic Errors Identified in 12 Major Cancer Types
Biomarker Helps Guide Treatment of Melanoma
Analytic Validation of Cancer Genomic Profiling Assay Demonstrated
Inherited Gene Variation Linked to Relapsing Pediatric Leukemia
Potential Biomarkers Found for Early Alzheimer's Diagnosis
Novel Test Improves Detection of Thyroid Cancer, Reduces Unnecessary Surgeries
Spinal Fluid Biomarkers Predict Cognitive Decline in Individuals with Familial Risk of Alzheimer's Disease
Qiagen and Clovis Oncology Jointly to Develop Companion Diagnostic
Genetic Disease Causes Recurrent Respiratory Infections
Genetic Testing channel of LabMedica brings the latest in molecular genetics, cytogenetics, and epigenetics, and methods from PCR to FISH, and more.








